Metabolic syndrome as a risk factor for barrett esophagus: A population-based case-control study

Mayo Clinic Proceedings

Volumn 88, Issue 2, 2013, Pages 157-165

  Leggett, Cadman L ^a   Nelsen, Eric M ^a   Tian, Jianmin ^a   Schleck, Cathy B ^a   Zinsmeister, Alan R ^a   Dunagan, Kelly T ^a   Locke, G Richard ^a   Wang, Kenneth K ^a   Talley, Nicholas J ^a,b   Iyer, Prasad G ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BARRETT ESOPHAGUS; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM QUESTIONNAIRE; GENDER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POPULATION BASED CASE CONTROL STUDY; QUESTIONNAIRE; RISK FACTOR; SENSITIVITY ANALYSIS; SMOKING; UNITED STATES;

EID: 84876532762     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.09.017     Document Type: Article

References (36)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303(3):235-241.
2. Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev. 2008;17(2):352-358. (Pubitemid 351272786)
3. Ryan AM, Healy LA, Power DG, et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg. 2008;247(6):909-915. (Pubitemid 351770409)
4. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology. 2007;133(1):34-41. (Pubitemid 47031134)
5. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer. 2008;44(2):293-297.
6. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54(2):463-471.
7. Rosato V, Tavani A, Bosetti C, et al. Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and metaanalysis. Metabolism. 2011;60(10):1372-1378.
8. Pelucchi C, Negri E, Talamini R, et al. Metabolic syndrome is associated with colorectal cancer in men. Eur J Cancer. 2010; 46(10):1866-1872.
9. Ortiz AP, Thompson CL, Chak A, Berger NA, Li L. Insulin resistance, central obesity, and risk of colorectal adenomas. Cancer. 2012;118(7):1774-1781.
10. El-Serag HB, Kvapil P, Hacken-Bitar J, Kramer Jr. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol. 2005;100(10):2151-2156.
11. Greer KB, Thompson CL, Brenner L, et al. Association of insulin and insulin-like growth factors with Barrett's oesophagus. Gut. 2012;61(5):665-672.
12. Cook MB, Greenwood DC, Hardie LJ, Wild CP, Forman D. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol. 2008; 103(2):292-300. (Pubitemid 351248722)
13. Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL. Central adiposity and risk of Barrett's esophagus. Gastroenterology. 2007;133(2):403-411. (Pubitemid 47187351)
14. Nelsen EM, Kirihara Y, Takahashi N, Shi Q, et al. Distribution of body fat and its influence on esophageal inflammation and dysplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2012;10(7):728-734.
15. Chung SJ, Kim D, Park MJ, et al. Metabolic syndrome and visceral obesity as risk factors for reflux oesophagitis: a crosssectional case-control study of 7078 Koreans undergoing health check-ups. Gut. 2008;57(10):1360-1365.
16. Nam SY, Choi IJ, Ryu KH, Park BJ, Kim HB, Nam BH. Abdominal visceral adipose tissue volume is associated with increased risk of erosive esophagitis in men and women. Gastroenterology. 2010;139(6):1902-1911.
17. St Sauver JL, Grossardt BR, Yawn BP, Melton LJ III, Rocca WA. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project. Am J Epidemiol. 2011;173(9):1059-1068.
18. Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol. 2011;106(8):1447-1455.
19. Rey E, Locke GR III, Jung HK, et al. Measurement of abdominal symptoms by validated questionnaire: a 3-month recall timeframe as recommended by Rome III is not superior to a 1-year recall timeframe. Aliment Pharmacol Ther. 2010;31(11):1237-1247.
20. Kubo A, Levin TR, Block G, et al. Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology. 2009;136(3):806-815.
21. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology. 1996;111(1):85-92. (Pubitemid 26226887)
22. Grundy SM, Brewer HB Jr., Cleeman JI, Smith SC Jr., Lenfant C; National Heart, Lung, and Blood Institute; American Heart Association. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004;24(2):e13-e18.
23. Consultation W. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Geneva, Switzerland: World Health Organization; 1999:31-33.
24. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition: a Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5): 469-480.
25. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28(9):2289-2304. (Pubitemid 41242486)
26. Roberts RO, Geda YE, Knopman DS, et al. Metabolic syndrome, inflammation, and nonamnestic mild cognitive impairment in older persons: a population-based study. Alzheimer Dis Assoc Disord. 2010;24(1):11-18.
27. Lee YC, Yen AM, Tai JJ, et al. The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease. Gut. 2009;58(2):174-181.
28. Oka R, Miura K, Sakurai M, et al. Comparison of waist circumference with body mass index for predicting abdominal adipose tissue. Diabetes Res Clin Pract. 2009;83(1):100-105.
29. Ryan AM, Duong M, Healy L, et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol. 2011;35(4):309-319.
30. Kendall BJ, Macdonald GA, Hayward NK, et al. Leptin and the risk of Barrett's oesophagus. Gut. 2008;57(4):448-454. (Pubitemid 351442525)
31. McElholm AR, McKnight AJ, Patterson CC, Johnston BT, Hardie LJ, Murray LJ. A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence. Gastroenterology. 2010;139(2):204-212.
32. Donohoe CL, Doyle SL, McGarrigle S, et al. Role of the insulinlike growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma. Br J Surg. 2012;99(3):387-396.
33. Doyle SL, Donohoe CL, Finn SP, et al. IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am J Gastroenterol. 2012;107(2):196-204.
34. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129(6):1825-1831. (Pubitemid 41772961)
35. Cho JH, Kim HM, Ko GJ, et al. Old age and male sex are associated with increased risk of asymptomatic erosive esophagitis: analysis of data from local health examinations by the Korean National Health Insurance Corporation. J Gastroenterol Hepatol. 2011;26(6):1034-1038.
36. Nozu T, Komiyama H. Clinical characteristics of asymptomatic esophagitis. J Gastroenterol. 2008;43(1):27-31. (Pubitemid 351324982)